Bivigam

BIOLOGICAL2 trials

Sponsors

ADMA Biologics, Inc.

Conditions

Humoral Immune ResponsePrimary Immune Deficiency Disorder

Phase 4

Study to Evaluate Safety and Pharmacokinetics of BIVIGAM® in Primary Immune Deficiency Subjects Aged 2 to 16

CompletedNCT03164967

ADMA Biologics, Inc.Humoral Immune Response

Start: 2016-12-29End: 2022-12-31Updated: 2023-02-01

Unknown Phase

A Study About Low Blood Pressure in Patients With Primary Immunodeficiency Disease Treated With Immune Globulin Products

ADMA Biologics, Inc.Primary Immune Deficiency Disorder

Start: 2016-12-31End: 2023-06-30Updated: 2023-02-01

Related Papers

Pharmacokinetic Model Based Sensitivity Analysis to Lower Recruitment Burden for Young Children Requiring Intravenous Immunoglobulin G Replacement.

2026-06-01

Population Pharmacokinetic Modeling and Simulation of Immune Globulin Intravenous (Human), 10% Liquid in Pediatric and Adult Patients with Primary Immune Deficiency Disorders

Journal of Human Immunity2025-04-25